Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Icosavax
Biotech
AstraZeneca enters RSV vaccine race with $800M Icosavax buy
The acquisition of RSV shot developer Icosavax suggests the British Big Pharma plans to be a vaccine player for a while longer.
James Waldron
Dec 12, 2023 5:19am
Icosavax's COVID-19 shot fails to deliver in early data
Mar 25, 2022 9:59am
Icosavax raises $100M to take RSV, COVID-19 vaccines into clinic
Apr 7, 2021 8:35am
Icosavax raises $51M to take VLP RSV vaccine into humans
Oct 3, 2019 9:00am